​

Rallybio (RLYB) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChart

Rallybio Revenue Highlights

Latest Revenue (Y)

$636.00K

Latest Revenue (Q)

$299.00K

Main Segment (Y)

Collaboration And License Revenue

Rallybio Revenue by Period

Rallybio Revenue by Year

DateRevenueChange
2024-12-31$636.00K100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Rallybio generated $636.00K in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Rallybio Revenue by Quarter

DateRevenueChange
2024-09-30$299.00K-
2024-06-30$299.00K100.00%
2024-03-31--100.00%
2023-12-31$228.00K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Rallybio generated $299.00K in revenue during Q3 2024, up 0.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Rallybio Revenue Breakdown

Rallybio Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
Collaboration And License Revenue$636.00K

Rallybio's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration And License Revenue (100.00%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24
Collaboration And License Revenue$337.00K$299.00K

Rallybio's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaboration And License Revenue (100.00%).

Rallybio Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
GLUEMonte Rosa Therapeutics$75.62M$4.70M
CCCCC4 Therapeutics$20.76M-
MOLNMolecular Partners$7.04M$2.74M
IPSCCentury Therapeutics$6.59M$791.00K
MNOVMediciNova$1.00M-
RLYBRallybio$636.00K$299.00K
OPTOpthea$108.41K$61.27K
CGEMCullinan Oncology--
ANTXAN2 Therapeutics--
PHVSPharvaris--
EWTXEdgewise Therapeutics--
MLYSMineralys Therapeutics--
THRDThird Harmonic Bio--
PEPGPepGen--
PMVPPMV Pharmaceuticals--

RLYB Revenue FAQ

What is Rallybio’s yearly revenue?

Rallybio's yearly revenue for 2024 was $636K, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. RLYB's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Rallybio’s quarterly revenue?

Rallybio's quarterly revenue for Q3 2024 was $299K, a 0% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $299K, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). RLYB's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023).

What is Rallybio’s revenue growth rate?

Rallybio's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Rallybio’s revenue streams?

Rallybio's revenue streams in c 24 are Collaboration And License Revenue

What is Rallybio’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Rallybio was Collaboration And License Revenue. This segment made a revenue of $636K, representing 100.00% of the company's total revenue.